相关实验视频
Updated: Jan 6, 2026

08:36
Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
Published on: April 7, 2023
1.5K
阿布罗西提尼布用于头部和部皮肤炎:病例系列和文献审查
Chuan Liu1, Yu Pan1, Jianxia Xiong1
1Department of Dermatology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, People's Republic of China.
Clinical, cosmetic and investigational dermatology
|November 26, 2025
概括
亚努斯激酶 (JAK) 抑制剂,如阿布罗西替尼 (abrocitinib),可以快速缓解头皮炎 (HND). 这些JAK抑制剂显示出作为耐火性HND的有效一线治疗方法的承诺,提供持续的症状控制.
科学领域:
- 皮肤病学 皮肤病学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 头皮炎 (HND) 是一种严重的亚托皮性皮炎 (AD),通常对标准治疗有抗性.
- 对HND的常规疗法包括局部皮质类固醇,氨酸抑制剂和生物药物,如dupilumab.
- 简氏激酶 (JAK) 抑制剂代表了一种新的治疗类别,向HND的关键炎症途径.
研究的目的:
- 评估abrocitinib在耐火性HND患者中的疗效.
- 为了比较abrocitinib与其他JAK抑制剂的有效性,特别是upadacitinib和baricitinib,用于HND治疗.
主要方法:
- 对三名接受abrocitinib (100-200毫克/天) 治疗的HND患者的回顾性分析.
- 使用湿疹区域和严重性指数 (EASI) 和研究人员的全球评估 (IGA) 评分来评估治疗反应.
- 对abrocitinib与其他JAK抑制剂在HND中的比较文献综述通过PubMed.
主要成果:
- 在所有患者中,阿布罗西提尼布治疗导致皮肤病变在1-2周内迅速改善,并在第8周几乎完全清除.
- 结果与临床数据一致,显示JAK抑制剂对HND的早期疗效.
- 阿布罗西提尼布和阿帕达西提尼布显示出强烈的临床反应,而巴里西提尼布对头病变的疗效较低.
结论:
- 包括abrocitinib和upadacitinib在内的Janus激酶 (JAK) 抑制剂是对耐火性HND的潜在一线治疗方法.
- 这些疗法提供迅速的症状缓解和持久的有效性.
- 进一步的研究可能会巩固JAK抑制剂在治疗严重HND中的作用.
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
435
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
435
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
447
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
447
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
402
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
402
NF-κB-dependent Signaling Pathway
9.7K
The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The...
NF-κB-dependent Signaling Mechanism
The...
9.7K

